Challenge the Performance of Your Hot-Start PCRs,,,with FastStart Taq DNA Polymerase and,,,the Novel FastStart High Fidelity PCR System
FastStart Taq DNA Polymerase a chem... ... ... The most versatile enzyme preparationcurrently available ...
The FastStart Taq DNA Polymerase
FastStart Taq DNA Polymerase, a chemically modified version
of Taq DNA Polymerase for hot start PCR, was introduced
in 2000. Based on the feedback from many customers,
FastStart Taq DNA Polymerase has proven to be:
The most robust enzyme preparation
currently available
Even the most challenging PCRs are no longer a problem.
In applications where other polymerases stop working,
FastStart Taq DNA Polymerase gives effective results
(Figures 1, 2, and 3).
The most versatile enzyme preparation
currently available
FastStart Taq DNA Polymerase is also the enzyme of
choice for real-time quantitative PCR, e.g., as applied on
the LightCycler Instrument. It is also included in most
LightCycler System reagent kits.
The FastStart High Fidelity PCR System
The novel FastStart High Fidelity PCR System contains
the new FastStart High Fidelity Enzyme Blend: a new
blend of FastStart Taq DNA Polymerase and a
thermostable proofreading protein that mediates proofreading
activity, but has no polymerase activity itself.
This enzyme blend is inactive at temperatures below
75C and does not elongate nonspecific primer-template
hybrids that may form during PCR setup. After activation
via a two-minute incubation step at 95C, the processivity
of FastStart Taq DNA Polymerase, and the ability
of the proofreading protein to recognize and excise
incorrectly incorporated nucleotides, combine
'"/>
Source:
Page: All 1 2 Related biology technology :1.
The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature2.
Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase3.
Comparing Fidelity and Performance of Proofreading PCR Enzymes4.
PCR Performance Comparisons Between pfuturbo and Taq DNA
Polymerases5.
pfuturbo DNA Polymerase:
A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning6.
Performance Comparisons of Commercial RT-PCR Systems7.
Restriction Endonucleases Undergo Rigorous QC Testing to Ensure Optimal
Performance8.
Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR
Performance9.
Versatile Transfection Reagent Offers Low Toxicity and Consistent
Performance10.
Highly Sensitive microRNA Array Performance11.
High Throughput RNA Isolation for High Performance Microarray Analysis
(Date:11/6/2009)...Intarcia Therapeutics, Inc. delivered two presenta...s delivery of exenatide) program for the treatment...echnology Meeting in San Francisco, CA: ,, (Log...FTU126LOGO ) ,, Continuous Subcutaneous Deliv...e, HbA1c and Reduces Weight in a 28-day Phase 1b S...
(Date:11/5/2009)...rstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today an...r ended September 30, 2009. GenVec reported a net ...ee months ended September 30, 2009 compared to a n...omparable quarter of 2008. For the nine months end... million ($0.15 per share), compared to a net loss...
(Date:11/5/2009)... -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), a... CEO of Imagenetix, will be presenting the Company...Thursday, December 3rd, at 10:30 AM PST at the Lux..., LD MICRO is a by-invitation only newsletter firm...the micro-cap space. Since 2002, the firm has publ...
(Date:11/5/2009)...l/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO...r ended September 30, 2009. The Company,s financia... ,, Third Quarter 2009 ,, The Company repo... the third quarter of 2009 as compared to a net lo...arter of 2008. ,, Net sales were $5.0 million ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7...by EBS is without merit and part of its overall st...iness without getting shareholder, approval and t...nding to PSC., -...o pursue its business, strategy of obtaining FDA a... and seeking additional federal and third party...
...evenues increased 38% to $42.3 million Full...n, SHANGHAI, China, July 10 /Xinhua-PRNewswire-Fi...d: CHBT) ("China-Biotics", "the,Company"), a leadi...search, development, marketing and distribution of... results for the fourth quarter and fiscal,year en...
...nce, July 10 , - 1st Half-Year Sales Up 16%, - ...reater than or equal,to)12%, EUR millions .../07 EURM %Sales EURM %S... change chang... 13 26.8 71 15 Other EU countries (2) ...
Other Biology Technology:Protein Sciences Responds to Emergent BioSolutions Lawsuit 2Protein Sciences Responds to Emergent BioSolutions Lawsuit 3Protein Sciences Responds to Emergent BioSolutions Lawsuit 4Protein Sciences Responds to Emergent BioSolutions Lawsuit 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 13Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2...mal model for the painful nerve condition known as...at it, according to Duke University bioengineers a... but rather a diverse range of symptoms, such as n...adiating leg pain or difficulty in controlling the...ng, of any of the five nerve roots that combine to...
...at Scripps Institution of Oceanography at UC San D...tures below the cobalt blue waters of Lake Tahoe o...ripps research team offer a more comprehensive ana...ion, which suggest a magnitude-7 earthquake occurs... the largest fault in the basin, West Tahoe, appea...
...en using a growing volume of genetic data to debat...to the New World in one wave or successive waves, ... of different populations. , Now, after painstaki...f modern-day Native American and Eurasian groups, ...put the matter to rest: Virtually without exceptio...
Other Biology News:Limping rat provides sciatica insights 2Scripps studies offer new picture of Lake Tahoe's earthquake potential 2Native Americans descended from a single ancestral group, DNA study confirms 2Native Americans descended from a single ancestral group, DNA study confirms 3... V is a fully integrated system for fluorescent b...that deliver excellent quality microarray images. ...er that is based on patented confocal laser imagin...spatial resolution. The DNAscope V images two fluo...
Rabbit Anti-Ca2+ Channel Ca gamma 2 Polyclonal Antibody, Unconjugated from BD Biosciences Pharmingen
Rabbit Anti-Nuclear Receptor Coactivator 2 (NCOA2) Polyclonal Antibody, Agarose Conjugated from Novus Biologicals
Anti-Monocarboxylate Transporter 2 (MCT2) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: